Glycated peptides are associated with proximal tubule dysfunction in type 2 diabetes mellitus

Ligia Petrica1, Adrian Vlad2, Gheorghe Gluhovschi1, Alina Zamfir3, Cristina Popescu4, Florica Gadalean1, Victor Dumitrascu5, Daliborca Vlad6, Roxana Popescu6, Silvia Velcio1, Cristina Gluhovschi1, Flaviu Bob1, Oana Milas7, Sorin Ursoniu8

1Department of Nephrology, 2Diabetes and Metabolic Diseases, 5Pharmacology, 6Cellular Biology, 8Public Health Medicine, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania; 3National Institute for Research and Development of Electrochemistry and Condensed Matter, Timisoara, Romania; 4Department of Experimental and Applied Biology, Institute of Life Sciences, “Vasile Goldis” Western University, Arad, Romania; 7Department of Nephrology, County Emergency Hospital, Timisoara, Romania

Received December 5, 2014; Accepted January 25, 2015; Epub February 15, 2015; Published February 28, 2015

Abstract: Background: Advanced glycation end-products have been involved in the pathogenesis of proximal tubule dysfunction which characterizes diabetic tubulopathy. Methods: A total of 76 Type 2 diabetes mellitus patients and 28 healthy controls were evaluated concerning a potential association of glycated peptides with proximal tubule dysfunction by assessing urine albumin:creatinine ratio, urinary alpha1-microglobulin, urinary neutrophil gelatinase-associated lipocalin, plasma asymmetric dimethyl-arginine, serum cystatin C. Fully automated chip-nanoelectrospray ionization and high-capacity ion trap multistage mass spectrometry characterized the urinary proteomic profile. Results: The urinary glycated proteins displayed a molecular weight of 15,121.4 Da in normoalbuminuric patients and of 30,180.4 Da in microalbuminuric patients. Urinary alpha1-microglobulin and neutrophil gelatinase-associated lipocalin correlated with urinary advanced glycation end-products (R2=0.586; R2=0.415), urine albumin: creatinine ratio (R2=0.292; R2=0.116), estimated glomerular filtration rate (R2=0.172; R2=0.135), serum cystatin C (R2=0.146; R2=0.129), but not with asymmetric dimethyl-arginine. In multivariable regression analysis models, the correlations for urinary alpha1-microglobulin and neutrophil gelatinase-associated lipocalin remained significant with urine albumin: creatinine ratio, urinary advanced glycation end-products, estimated glomerular filtration rate (P<0.0001, R2=0.674; P<0.0001, R2=0.551; P<0.0001, R2=0.482). Conclusions: In patients with Type 2 diabetes mellitus urinary glycated peptides are associated with proximal tubule dysfunction. The proteomic patterns of urinary glycated peptides could differentiate normo- from microalbuminuric patients and may explain a potential relation between the size and the glycation status of glycated peptides, and the extent of proximal tubule dysfunction. The lack of correlation between parameters of endothelial dysfunction and proximal tubule dysfunction cannot exclude glomerular involvement in early diabetic nephropathy.

Keywords: Glycated peptides, proximal tubule, normoalbuminuria, Type 2 diabetes mellitus

Introduction

Diabetes mellitus (DM) is now the leading cause of end-stage renal disease worldwide and may be attributed up to 20-40% of cases referred to renal replacement therapies, both in developed and emerging countries [1].

Currently, there is a debate as to whether early diabetic nephropathy (DN) in Type 2 DM may be attributed to the glomerulus or to the proximal tubule (PT). It is assumed that albuminuria is caused primarily by impaired tubular uptake of intact albumin rather than by an increased leakiness of the glomerular filtration barrier [2, 3]. In previous works performed by us in normoalbuminuric patients with Type 2 DM we demonstrated that PT dysfunction precedes the occurrence of albuminuria and is dissociated from endothelial dysfunction [4, 5]. Multiple markers of endothelial dysfunction have also been documented in normoalbuminuric subjects with Type 2 DM, suggesting that the vasculopathy occurs before the development of microalbuminuria [5, 6].
Amongst other causative factors related to PT dysfunction, advanced glycation end-products (AGE) have been involved in the pathogenesis of diabetic tubulopathy, an emerging entity [7]. Low-molecular weight AGE are filtered by renal glomeruli and then reabsorbed and metabolized by the PT. AGE activate PT cells [8], and severely modified albumin molecules after binding to advanced glycation addsucts display high labelling in the urinary space and endocytic compartments of PT cells. Most likely, PT dysfunction is initiated by various types of peptide fragments, among which glycated peptides are of major importance [8, 9]. There is an ongoing debate as to what extent albumin per se is nephrotoxic and whether modification of albumin and its altered molecules, such as glycated albumin, induce a degree of nephrotoxicity [10]. Recently, it has been stated that plasma albumin fragments have a different pattern from urinary albumin fragments, which do not originate from intracellular degeneration in the kidney PT, but they may be filtered from plasma into the urine and become later a tubulotoxic component [11].

The aim of our study was to investigate a potential association of urinary glycated peptides with PT dysfunction in patients with Type 2 DM. Also, we hypothesized that the expression of glomerular endothelial dysfunction and the onset of microalbuminuria may be delayed by the PT albumin processing in early DN, a phenomenon which could be impaired by glycated peptides involvement.

Materials and methods

A total of 76 patients with Type 2 DM attending the Outpatient Department of Diabetes and Metabolic Diseases and 28 healthy control subjects were enrolled in a cross-sectional study from January 2013 through July 2013. The inclusion criteria were duration of DM higher than 5 years, normoalbuminuria [urine albumin:creatinine ratio (UACR) <30 mg/g] or microalbuminuria (UACR between 30 and 300 mg/g), therapy with oral antidiabetic drugs, angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers, and statins. Patients were divided in two groups: 40 patients with normoalbuminuria (group 1) and 36 patients with microalbuminuria (group 2).

The County Emergency Hospital Ethics Committee (Board of Human Studies) approved the protocol (approval number 4/11.01.2013), and every patient provided written informed consent before enrolment.

All patients were assessed concerning UACR; urinary alpha-1-microglobulin and urinary neutrophil gelatinase-associated lipocalin (NGAL), as biomarkers of PT dysfunction; plasma and urinary AGE; plasma asymmetric dimethyl-arginine (ADMA), as a biomarker of endothelial dysfunction; and serum cystatin C. Fully automated chip-nanoelectrospray ionization and high-capacity ion trap multistage mass spectrometry characterized the urinary proteomic profile.

Serum and urinary biomarkers were determined in specimens frozen at -80°C and thawed before assay. CKD was defined according to the KDIGO Guideline for the Evaluation and Management of CKD (2009 CKD-EPI creatinine equation) [12].

Plasma ADMA was evaluated by the ELISA method with K7828 ADMA ELISA Kit (Immunoagnostik AG, Bensheim, Germany). The reference interval was 0.45±0.19 μmol/l. The intra-assay precision was 6.2-10.5% (0.27±0.021 μmol/l; 0.78±0.041 μmol/l), while the inter-assay precision was 6.2-7.9% (0.33±0.029 μmol/l; 0.79±0.045 μmol/l).

Cystatin C was assessed in serum with N Latex Cystatin C Kit (Siemens Healthcare Diagnostics, Marburg, Germany) through particle-enhanced immunonephelometry using the BNProSpec System. The reference interval was calculated nonparametrically and was determined to be 0.53-0.95 mg/l. The intra-assay precision was 2.5% coefficient of variation (CV) and inter-assay precision was 2.0% CV with a total of 2.8% CV. Analytical sensitivity was calculated as two standard deviations above the mean signal of 20 replicates of N diluent and was determined to be 0.005 mg/l. A typical detection for N Latex Cystatin C is 0.05 mg/l.

Alpha-1-microglobulin was evaluated in the second morning urine specimen with N α1-Microglobulin Kit (Siemens Healthcare Diagnostics, Marburg, Germany) through particle-enhanced immunonephelometry using the BNProSpec System. The reference interval was 12 mg/l or 0.07-5 mg/g creatinine. The intra-assay precision was 2.9-5.2% CV, while the inter-assay precision was 7.4-13.2% CV.
Albuminuria was measured in the second morning urine specimen through immunonephelometry on the BNProSpec System, with N Antiserum to Human Albumin (Siemens Healthcare Diagnostics, Marburg, Germany). Microalbuminuria was defined by UACR between 30 and 300 mg/g, and normoalbuminuria by UACR <30 mg/g. The N Antiserum to Human Albumin was evaluated for the assay of urine on a BN System and yielded a Within-Run CV of 2.2% and a total CV of 2.6% with a mean of 79 mg/l. The results (ten runs, four determinations per run) were evaluated by analysis of variance. Urine cultures were negative for bacteriuria in all patients.

Urinary NGAL was assessed in the second morning urine specimen by the ELISA method with the NGAL Rapid Elisa Kit 037 (BioPorto Diagnostics, Gentofte, Denmark). The reference interval was 4.3-12.0 ng/ml. Intra-assay variation was determined by measurement of urinary NGAL in two 24-hour urine samples with 8 replicates (CV=3.4-4.3%). Inter-assay variation was determined by measurement of urinary NGAL in two diluted 24-hour urine samples with 2 replicates in 4 separate assays (CV=4.7-22.7%).

Plasma and urinary AGE peptides were assessed in a 24-hour urine sample by the ELISA method with Human Advanced Glycosylation End-Products ELISA Kit (E01A0002), Shanghai Blue Gene Biotech Co., Shanghai, China. The sensitivity in this assay measured in two 24-hour urine samples was 1.0 pg/ml. This assay has high sensitivity and excellent specificity of AGE, and contains polyclonal antibodies which assess protein-bound AGE. The system utilized only allows the assessment of both high and low molecular AGE species. No significant cross-reactivity or interference between AGE and analogues was observed.

Proteomic analysis of urinary glycated peptides

Protein isolation and electrophoresis: 0.5 ml of urine was centrifuged at 3500 rpm for 5 min at 4°C to pellet out the cells/debris if any. Proteins from 0.5 ml of the supernatant were isolated using Acetone Precipitation overnight. The pellet was vacuum dried. 10 µg protein sample was loaded on 12% SDS-PAGE protein gel and electrophoresis was carried out on an SE260 Mighty Small II device from Hoefer, Inc. The electrophoresis running buffer was prepared from a 10x Tris-glycine-SDS solution. Electrophoresis was carried out at 120 V and an initial current of ~32 mA using a PowerPac 1000 power supply (Bio-Rad; Hercules, CA) and was terminated when the dye front reached close to the bottom of the gel. Typical run times were 1.5-2 h.

Gel staining: Immediately following electrophoresis, the gels were stained with 0.25% Comassie Blue R-250 (Sigma) overnight, followed by destaining for 4H in 5% MeOH, 7.5% HOAC, 87.5% H2O. Coomassie removal was carried out using Blue-Out reagent from G-Biosciences according to manufacturer instructions. Protein bands of 64, 55, 50, 40, 36, and 30 kDa, respectively, were obtained. Due to the fact that urinary glycated peptides (most likely their fragments), potentially involved in PT dysfunction, display low-molecular weight, further analysis was only performed in the bands of 30 kDa, which were excised from the stained gel with a clean, sharp straight-edge razor. The gel slices were excised as close as possible to the boundaries of the protein band.

Mass spectrometry

Reagents and materials: Methanol and formic acid were from Merck (Darmstadt, Germany). All reagents and solvents were of highest available purity. Prior to analysis, the sample solution eluted from the 30 kDa bands was centrifuged for 2 hours in a Sigma 2-16 model centrifuge from Sartorius (Göttingen, Germany). The supernatant was collected and submitted to chip-nanoelectrospray ionization analysis.

Mass spectrometry experiments were conducted on a High Capacity Ion Trap Ultra (HCT Ultra, PTM discovery) mass spectrometer (Bruker Daltonics, Bremen, Germany). Spectra were
acquired in the 100-3000 m/z range in positive ion mode detection with a scan speed of 8000 m/z per second. G2421A “tuning mix” (Agilent Technologies, Santa Rosa, CA, USA) was used for calibration.

For Nano Mate-MS experiments the protein was dissolved in Me OH/formic acid (1:1 v:v) to approximately 0.5 pmol/mL concentration. The sample was infused by fully automated chip-based nanoelectrospray conducted on a Nano Mate robot incorporating ESI 400 Chip technology (Advion BioSciences, Ithaca, USA), controlled and manipulated by Chip Soft 8.1.0 Software operating under Windows system. The robot was coupled to the HCT via an in-laboratory made mounting system which allows the whole robot positioning on O-xyz with respect to MS inlet, as described by us previously [14]. The Nano Mate was mounted on the HCT mass spectrometer, by the aid of an in-laboratory made bracket. To initiate the electro spray in the positive ion mode, a voltage of 1.3-1.5 kV was imposed on the pipette tip, while the chip was grounded. The spray was enhanced by the application of 0.3-0.40 psi nitrogen back pressure, and 50 psi pressure of nitrogen nebulizer on MS. For optimal dissolution of the sample droplets, the source block was maintained at a constant temperature of 100°C. The in-source fragmentation was prevented by keeping a potential difference between the ends of the transfer capillary and the skimmer (capillary exit) at 50 V.

For all experiments a glass-coated micro titer plate was used, thus preventing any risk of cross-contamination. Aliquots of the working sample solutions were loaded onto the 96-well glass plate. The robot was programmed to aspirate the sample and then deliver it to the inlet side of the microchip. The unused sample was returned into its original well after each measurement. Disposable conductive pipette tips

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group 1</th>
<th>Group 2</th>
<th>Controls</th>
<th>p*</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subjects</td>
<td>40</td>
<td>36</td>
<td>28</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Age (years)</td>
<td>57.16±7.83</td>
<td>59.04±9.33</td>
<td>57.18±4.95</td>
<td>0.3834</td>
<td>0.8396</td>
</tr>
<tr>
<td>DM duration (years)</td>
<td>10.08±4.04</td>
<td>10.45±5.14</td>
<td>-</td>
<td>0.7448</td>
<td>-</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>32.67±6.19</td>
<td>31.38±6.62</td>
<td>24.22±0.45</td>
<td>0.4320</td>
<td>0.0175</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>131.56±12.59</td>
<td>132.5±9.72</td>
<td>121.36±7.44</td>
<td>0.7583</td>
<td>0.0018</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>76.87±8.22</td>
<td>75.22±8.08</td>
<td>65.90±6.25</td>
<td>0.437</td>
<td>0.0048</td>
</tr>
<tr>
<td>Hb (g/dl)</td>
<td>12.90±1.15</td>
<td>12.82±0.74</td>
<td>13.90±0.75</td>
<td>0.252</td>
<td>0.0186</td>
</tr>
<tr>
<td>Serum creatinine (mg/dl)</td>
<td>0.95±0.20</td>
<td>0.98±0.17</td>
<td>0.80±0.09</td>
<td>0.5055</td>
<td>0.0095</td>
</tr>
<tr>
<td>eGFR (ml/min/1.73 m²)</td>
<td>76.51±16.43</td>
<td>71.80±15.14</td>
<td>90.00±5.76</td>
<td>0.3321</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Glycaemia (mg/dl)</td>
<td>146.79±37.21</td>
<td>147.54±57.36</td>
<td>92±7.07</td>
<td>0.9476</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>HbA₁c (%)</td>
<td>6.97±0.62</td>
<td>7.11±1.05</td>
<td>5.99±0.17</td>
<td>0.4863</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Serum cholesterol (mg/dl)</td>
<td>216.20±49.19</td>
<td>220.13±49.29</td>
<td>157.18±23.47</td>
<td>0.7576</td>
<td>0.0014</td>
</tr>
<tr>
<td>Serum triglycerides (mg/dl)</td>
<td>144.54±47.50</td>
<td>151.95±48.03</td>
<td>96.45±25.61</td>
<td>0.3124</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>hsCRP (mg/dl)</td>
<td>6.68±4.05</td>
<td>13.29±5.54</td>
<td>0.93±0.18</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>UACR (mg/g)</td>
<td>16.8±6.34</td>
<td>70.09±34.02</td>
<td>15.71±4.11</td>
<td>&lt;0.0001</td>
<td>0.0002</td>
</tr>
<tr>
<td>Urinary alpha₁/creat (mg/g)</td>
<td>3.31±1.34</td>
<td>5.72±2.13</td>
<td>2.07±0.62</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Urinary NGAL/creat (µg/g)</td>
<td>229.11±139.06</td>
<td>444.28±205.83</td>
<td>78.59±6.58</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Cystatin C (mg/l)</td>
<td>0.82±0.19</td>
<td>0.96±0.27</td>
<td>0.61±0.07</td>
<td>0.0157</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Urinary AGE (pg/ml)</td>
<td>44.33±17.42</td>
<td>70.97±37.12</td>
<td>31.54±1.43</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>ADMA (µmol/l)</td>
<td>0.44±0.19</td>
<td>0.60±0.23</td>
<td>0.26±0.01</td>
<td>0.0026</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Plasma AGE (pg/ml)</td>
<td>442.64±175.69</td>
<td>655.22±152.03</td>
<td>272.39±22.59</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

DM-diabetes mellitus; SBP-diastolic blood pressure; DBP-systolic blood pressure; Hb-haemoglobin; eGFR-estimated glomerular filtration rate; HbA₁c-glycated haemoglobin; hsCRP-high sensitive C reactive protein; UACR-urinary albumin:creatinine ratio; alpha₁/creat-alpha₁-microglobulin:creatinine ratio; urinary NGAL/creat-neutrophil gelatinase associated lipocalin: creatinine ratio; AGE-advanced glycation end-products; ADMA-asymmetric dimethyl-arginine; parameters are presented as means, standard deviations, and proportions; p*-Bonferroni’s test for the differences between groups 1 and 2; p-ANOVA analysis of variance to compare groups 1, 2, and controls.
were used throughout all experiments. After each measurement the pipette tip was ejected and a fresh tip and nozzle were used for the next experiment.

Statistical analysis

Clinical and biological data are presented as means, standard deviations, and proportions. We used ANOVA test and the Bonferroni multiple-comparison test. Univariable regression analyses were carried out to evaluate the significance of the relation between continuous variables for all 3 groups together (pooled data of normo- and microalbuminuric patients, and healthy controls). Only significant variables yielded by univariable regression analysis were introduced in the models for multivariable regression analysis. The p values for all hypothesis tests were two-sided, and statistical significance was set at P<0.05. All analyses were conducted with Stata 9.2 (Statacorp, Texas, USA).

Results

All patients and controls were included in the analysis.

Characteristics of the study subjects are presented in Table 1. The results of the univariable regression analysis concerning ADMA are presented in Table 2. Potential confounders for ADMA, such as age, hypertension, and the lipid profile have been included in the analysis.

A significant correlation was found between urinary alpha_1-microglobulin and urinary NGAL, and UACR, plasma and urinary AGE, estimated glomerular filtration rate (eGFR), and cystatin C, respectively (Table 3). After adjustment in multivariable regression analysis, the models showed that the correlations for urinary alpha_1-microglobulin and urinary NGAL remained significant with UACR, urinary AGE, and GFR (P<0.0001, R^2=0.674; P<0.001, R^2=0.551; P<0.0001, R^2=0.482) (Table 4).

The protein sample of 30 kDa analysed by fully automated chip-nanoelectrospray ionization and high-capacity ion trap multistage mass spectrometry provided a particular proteomic pattern of urinary protein-bound glycated peptides in both groups. We found that in the case of normoalbuminuric patients the urinary glycated protein displayed a molecular weight of 15,121.4 Da (Figure 1), while in the case of microalbuminuric patients, the molecular weight was almost two times this value, i.e. 30,180.4 Da (Figure 2). This difference in size indicates a significantly higher glycation status of the urinary glycoproteins in microalbuminuric patients.

Discussion

The results of our study showed increased levels of PT dysfunction biomarkers in both normo- and microalbuminuric patients. Urinary AGE correlated with the biomarkers of PT dysfunction studied, but not with plasma ADMA, a fact which documented a potential association of AGE with PT functional defects, even in the normoalbuminuria stage, before expression of glomerular endothelial dysfunction.

Proteomic mass spectrometry analysis revealed a particular pattern of urinary glycated peptides, the size of which differed in normoalbuminuric patients as compared to microalbuminuric patients.
Glycated peptides in proximal tubule dysfunction

uric patients. There occurred a slight decline in renal function as assessed by serum cystatin C, a fact which proves that patients with Type 2 DM might experience a steady decrease in their renal function, while remaining normoalbuminuric.

PT dysfunction is dissociated from and does not parallel glomerular endothelial dysfunction in early DN

The classical concept concerning albuminuria states that albuminuria is related to the severity of diabetic glomerular lesions, but this correlation is not strict in Type 2 DM due to the fact that these lesions may precede the onset of albuminuria [15]. Endothelial dysfunction may also occur in patients with Type 2 DM even when the patients are still normoalbuminuric, a fact demonstrated by markers of endothelial dysfunction which may be elevated years before any evidence of microangiopathic complications in both types of DM [16].

Nitric oxide (NO) is synthesized by the vascular endothelium from the aminoacid L-arginine by constitutive and inducible NO-synthase and plays an important role in the maintenance of vascular homeostasis. The endogenous L-arginine metabolite, ADMA, inhibits cellular

<table>
<thead>
<tr>
<th>Variable</th>
<th>Parameter</th>
<th>R-squared</th>
<th>Coef β</th>
<th>p</th>
<th>R-squared</th>
<th>Coef β</th>
<th>p</th>
<th>R-squared</th>
<th>Coef β</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>eGFR</td>
<td></td>
<td>0.178</td>
<td>-0.051</td>
<td>&lt;0.001</td>
<td>0.074</td>
<td></td>
<td></td>
<td>0.130</td>
<td>-0.602</td>
<td>0.001</td>
</tr>
<tr>
<td>Cystatin C</td>
<td></td>
<td>0.146</td>
<td>3.240</td>
<td>&lt;0.001</td>
<td>0.101</td>
<td>262.687</td>
<td>0.004</td>
<td>0.110</td>
<td>38.515</td>
<td>0.002</td>
</tr>
<tr>
<td>pAGE</td>
<td></td>
<td>0.132</td>
<td>36.69</td>
<td>0.001</td>
<td>0.089</td>
<td>4.60</td>
<td>0.007</td>
<td>0.058</td>
<td>1.777</td>
<td>0.03</td>
</tr>
<tr>
<td>UACR</td>
<td></td>
<td>0.292</td>
<td>0.035</td>
<td>&lt;0.001</td>
<td>0.282</td>
<td>3.398</td>
<td>&lt;0.0001</td>
<td>0.177</td>
<td>0.378</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>u alpha_1/creat</td>
<td></td>
<td>0.542</td>
<td>0.112</td>
<td>&lt;0.001</td>
<td>0.586</td>
<td>0.055</td>
<td>0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>uNGAL/creat</td>
<td></td>
<td>0.482</td>
<td>4.943</td>
<td>&lt;0.0001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 3. Univariable regression analysis for the tubular biomarkers

u alpha_1/creat: urinary alpha_1-microglobulin to creatinine ratio; uNGAL/creat: urinary neutrophil gelatinase-associated lipocalin to creatinine ratio; uAGE: urinary advanced glycation end-products; eGFR: estimated glomerular filtration rate; pAGE: plasma advanced glycation end-products; UACR: urinary albumin to creatinine ratio.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Variable</th>
<th>Coef β</th>
<th>p</th>
<th>95% CI</th>
<th>F</th>
<th>Prob&gt;F</th>
<th>R-squared</th>
</tr>
</thead>
<tbody>
<tr>
<td>u alpha_1/creat</td>
<td>Constant</td>
<td>0.863</td>
<td>0.002</td>
<td>0.323 to 1.403</td>
<td></td>
<td>53.14</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>eGFR</td>
<td></td>
<td>-0.025</td>
<td>0.003</td>
<td>-0.042 to -0.008</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>uNGAL/creat</td>
<td></td>
<td>0.002</td>
<td>0.009</td>
<td>0.0006 to 0.004</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UACR</td>
<td></td>
<td>0.012</td>
<td>0.016</td>
<td>0.002 to 0.022</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>uAGE</td>
<td></td>
<td>0.036</td>
<td>&lt;0.0001</td>
<td>0.023 to 0.050</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 4. Multivariable regression analysis for the tubular biomarkers

u alpha_1/creat: urinary alpha_1-microglobulin to creatinine ratio; uNGAL/creat: urinary neutrophil gelatinase-associated lipocalin to creatinine ratio; uAGE: urinary advanced glycation end-products; eGFR: estimated glomerular filtration rate; UACR: urinary albumin to creatinine ratio.
L-arginine uptake and NO-synthase activity. Circulating ADMA is elevated in patients with overt DN, even when the GFR is still within normal range [17].

It has been stated that in both normo- and microalbuminuric patients with DM, plasma ADMA levels have prognostic implications for the transition to a more advanced stage of albuminuria [18].

In our study, ADMA levels were increased in a small number of the normoalbuminuric patients and did not correlate with UACR and PT dysfunction biomarkers. Plasma ADMA correlated with inflammation, plasma cystatin C, GFR, and DM duration. These results are in contrast to near similar data found in microalbuminuric patients with Type 2 DM [19], thus giving rise to the speculation that an inflammatory state at the glomerular level may be found in normoalbuminuric patients with Type 2 DM.

Decreased peritubular capillary flow due to impaired levels of plasma ADMA may induce tubulointerstitial ischemia and subsequent modifications in the function of PT cells [20]. In patients with early DN diagnosed on PT abnormalities and markers of tubular dysfunction, the levels of ADMA may remain within the normal (or high-to-normal) range [18], as was the case with our patients.

Glycated peptides are associated with PT dysfunction biomarkers in early DN

The tubular theory concerning mechanisms of albuminuria in early DN states that there is a reduction in the retrieval pathway of albumin in the PT, and this impairment precedes glomerular damage [3]. Albumin per se is considered nephrotoxic [21] and modifications of albumin increase its capacity to exert nephrotoxic properties and to cause PT dysfunction and peritubular fibrosis [10].

AGE have been shown to modulate NO-synthase in endothelial cells [22]. In our study, urinary AGE did not correlate with ADMA, a biomarker of endothelial dysfunction, but only with biomarkers of PT dysfunction, thus showing that the expression of glomerular endothelial dysfunction is not conditional on the onset of albuminuria in early DN.

AGE-modified peptides show tubulotoxic effects and lead to pathophysiologic responses described as diabetic tubulopathy [7]. The data provided by our study lead to the assumption that urinary glycated peptides may be associated with PT function impairment, even in normoalbuminuric patients. The proteomic patterns of urinary glycated peptides found in our patients could differentiate normo- from micro-

Figure 1. Fully automated chip-nanoelectrospray mass spectrometry of urinary glycated peptide in a normoalbuminuric patient with Type 2 DM. Acquisition time 1 min; solvent: HCOOH/MeOH (1:1 v:v); ChipnanoESI: 1.3 kV; EndCap: 50 V; Skimmer: 40 V; Nitrogen back pressure: 0.30 p.s.i.; Nebulizer on MS at 50 psi.
albuminuric patients and may explain a potential relation between the size of glycated peptides and the extent of PT dysfunction. The difference in size of the glycated peptides between normo- and microalbuminuric patients indicates a significantly higher glycation status of the urinary glycoproteins in microalbuminuric patients.

Biomarkers of PT dysfunction are strongly associated to the levels of plasma and urinary AGE [10]. In our study we found a significant relation of plasma and urinary AGE with biomarkers of PT dysfunction, such as urinary alpha_1-microglobulin and urinary NGAL, even in normoalbuminuric patients. This association raises the possibility that renal tubular function defects precede the onset of microalbuminuria. Similar data have been provided by several studies performed in normoalbuminuric patients with Type 2 DM, in who increased levels of urinary alpha_1-microglobulin [4, 5, 23] and urinary NGAL [24] show that tubular functional defects precede the onset of albuminuria.

In our study, urinary alpha_1-microglobulin, urinary NGAL, plasma and urinary AGE-peptides correlated directly with serum cystatin C. Similarly, it has been revealed that urinary PT damage markers are associated with GFR and cystatin C, independently of albuminuria [24, 25].

It has been shown that reduced GFR may correlate with the degree of albuminuria within the normal range [4, 5, 26]. Subtle changes in renal function in patients with Type 2 DM, as assessed by serum cystatin C, may parallel the degree of albuminuria, even in high-to-normal albuminuria [27, 28], data which is similar to our findings. In our cross-sectional study, the declined GFR in normoalbuminuric patients should be regarded as an association with AGE-induced PT dysfunction, observation which does not necessarily prove causality. In a study performed in Type 1 and Type 2 DM patients it has been shown that urinary protein-bound AGE concentrations closely paralleled changes in albuminuria, reflecting the severity of DN [29]. This data is consistent with results from studies which support the hypothesis that renal function may show a steady decline in normoalbuminuric patients with Type 2 DM [30, 31].

Our study has some limitations. First, the small study cohort could affect the statistical power of the study. Second, the glycated peptides found in mass spectrometry require further identification. Finally, this is a cross-sectional
Glycated peptides in proximal tubule dysfunction

study which requires validation by a longitudinal study in order to prove causality between glycated peptides and PT dysfunction.

To sum up, urinary glycated peptides may be associated with PT dysfunction in patients with Type 2 DM. The proteomic patterns of urinary glycated peptides found in our patients could differentiate normo- from microalbuminuric patients and may explain a potential relation between the size of glycated peptides and the extent of PT dysfunction. This difference in size of the glycated peptides indicates a significantly higher glycation status of the urinary glycoproteins in microalbuminuric patients. We found a significant relation of plasma and urinary AGE with biomarkers of PT dysfunction in both normo- and microalbuminuric patients, association which raises the possibility that AGE-induced renal tubular function defects precede the onset of microalbuminuria. The expression of glomerular endothelial dysfunction and the onset of microalbuminuria may be delayed by the PT albumin processing in early DN, until AGE could induce PT dysfunction. Thus, the lack of correlation between parameters of endothelial dysfunction and of PT dysfunction cannot exclude glomerular involvement in early DN. Further prospective studies on larger cohorts are warranted in order to support these data.

Acknowledgements

This research received funding from an Internal Grant of “Victor Babes” University of Medicine and Pharmacy Timisoara, PIII-C1-PCFI-2014/2015. The supporting source had no involvement in study design, in collection, analysis, and interpretation of data, in the writing of the report, and in the decision to submit the manuscript for publication.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Adrian Vlad, Department of Diabetes and Metabolic Diseases, “Victor Babes” University of Medicine and Pharmacy, P-ta Eftimie Murgu 2, 300041 Timisoara, Romania. Tel: +40723010065; Fax: +40256462820; E-mail: vladrian@hotmail.com

References

Glycated peptides in proximal tubule dysfunction


